Trial intelligence / Profile preview

Infrared heat therapy versus cryotherapy as adjuncts to meglumine antimoniate for cutaneous leishmaniasis

IRCT20210823052264N5Phase 3Completed

Sponsor
Combined Military Hospital Quetta
Start
May 2024
Modality
Small Molecules
Countries
1
01

Overview

Phase 3, open-label trial of meglumine antimoniate in cutaneous leishmaniasis (CL) (3 arms), sponsored by Combined Military Hospital Quetta. Primary endpoint: Clinical response. Started May 2024; status: completed.

02

Drugs

meglumine antimoniate
03

Conditions

cutaneous leishmaniasis (CL)

Beyond the preview

Go deeper on IRCT20210823052264N5.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on IRCT20210823052264N5.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call